– Interview with Bruce Mackler, Ph.D., J.D., senior advisor on FDA matters and due diligence concerns to financial groups and investment companies

Previous articleAgilent Ups Therapeutic Nucleic Acids Manufacturing Capacity
Next articleDOR Licenses Anthrax Toxin Analogues from Harvard